COVID-19 Impact on Global Oncology Drugs Market By Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer and Other Cancers); By Type (Chemotherapy, Targeted Therapy, Immunotherapy and Hormonal Therapy) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030
November 2020
187
About the Report
About the Report
Product Overview
Oncology is a field of cancer science and care. Cancer is an illness in which abnormal cells expand and divide uncontrolled. Drugs oncology is helpful in the aid of cancer diagnosis. Tobacco and smoking, infectious diseases, genetic factors, carcinogens, bacterial infections, physical activity, dietary habits, and age are some of the causes of cancer. Blood cancer, endocrine cancer, prostate cancer, bone cancer, skin cancer, genitourinary cancer, gastrointestinal cancer, breast cancer, eye cancer, head and neck cancer, and gynecological cancer are all distinct forms of cancer that can be treated with oncology medicines.
Market Highlights
Global Oncology Drugs Market size was registered at USD 86.67 billion in 2019 and is estimated to reach USD 321.69 billion by 2030, registering a CAGR of 13.12% from 2020 to 2030. Technological innovation, increased occurrence of different types of cancers, increased need for cancer research and development activities, and increasing concerns about high cancer death rates are driving the oncology drug market. Furthermore, the launch of new cancer medicines and treatments and government funding for improving healthcare conditions are expected to drive the oncology drug market.
Global Oncology Drugs Market Opportunity Analysis
Source: Fatpos Global
Global Oncology Drugs Market: Segments
Oncology Drugs Market is segmented based on type, indication, and region.
By Type (in %), Oncology Drugs Market, 2019
The targeted therapy segment is anticipated to register XX% of the market share during the forecasted period.
By type, the market can be segmented into Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy. Due to the ability of targeted therapies to kill only malignant cells, better effectiveness, and higher survival rates associated with their use, the targeted therapy category has the highest oncology drug market share. During the forecast period, the immunotherapy segment is expected to show the fastest development. This is due to an increase in the prevalence of cancer in several countries worldwide and high unmet medical needs.
By Indication (in %), Oncology Drugs Market, 2019
The prostate cancer segment accounted for XX% of the nation’s volume in 2019
The indication segment can be classified into Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Other Cancers. The prostate cancer category controlled the largest market share for oncology drugs due to the presence of a huge geriatric population, according to the indication. During the forecast period, the lung cancer segment is expected to show the fastest rise. This is attributed to technological advances in cancer care and increased understanding of early cancer diagnosis.
Source: Fatpos Global
Global Oncology Drugs Market Dynamics:
Increasing research and development and government funding to increase the market growth
Technological innovation, increased occurrence of different types of cancers, increased need for cancer research and development activities, and increasing concerns about high cancer death rates are driving the oncology drug market. Furthermore, the launch of new cancer medicines and treatments and government funding for improving healthcare conditions are expected to drive the oncology drug market.
High cancer care costs and side effects of treatment to hinder the market growth
High cancer care costs, stringent government regulations, huge investment participation in therapy production and clinical trials, and side effects of cancer therapies are some of the major factors that limit growth for the global market for oncology drugs.
Global Oncology Drugs Market: Regions
In terms of value and volume, APAC accounted for XX% of total market volume share in 2019
Due to growing cancer awareness across the area and rising R&D spending, the APAC oncology drug market has high growth potential. Moreover, this area provides tremendous opportunities for venture capitalists and investors, as the established markets are relatively saturated. Also, some other factors contributing to the growth of the cancer drug market in this area are the increase in disposable income; the increase in research, development, and innovation activities; and the increase in awareness related to various cancers. Also, the widespread prevalence in countries such as Japan of certain cancers, such as stomach cancer, and the presence of a large geriatric population are driving market growth in this area.
The region segment can be further divided into five major types including North America, Latin America, Europe, APAC, and MENA.
Source: Fatpos Global
Global Oncology Drugs Market is further segmented by region into:
- North America Market Size, Share, Trends, Opportunities-o-Y Growth, CAGR – United States and Canada
- Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
- Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
- APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
- MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
Global Oncology Drugs Market: Impact of COVID-19
Global pandemic COVID-19 has become global stress, not just for human lives, but also for industries across different industry verticals. The COVID-19 disease has infected several million people globally, with an increasing number of active cases daily, the duration of the pandemic is still difficult to predict. The epidemic of COVID-19 has had a positive impact internationally on the demand for oncology drugs. Concerning emergency COVID-19, some consumer segments have experienced an increase in demand for medicines. Among cancer patients in the midst of a lockout, panic buying of drugs has been seen. In this segment, the pharmaceutical companies have dramatically strengthened their supply chain management, enhanced their R&D capabilities, and invested more in their production management and quality control.
Oncology Drugs Market: Competitive landscape
New technological advancements in the Oncology Drugs Market as well as large production output of the product by key players are likely to increase the market growth. In this segment, the pharmaceutical companies have dramatically strengthened their supply chain management, enhanced their R&D capabilities, and invested more in their production management and quality control.
Oncology Drugs Market: Key players
- Bayer AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Genentech, Inc.
- Novartis AG
- Pfizer Inc.
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc.
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Other prominent players
- Company Overview
Global Oncology Drugs Market report also contains analysis on:
Oncology Drugs Market segments: -
- By Type:
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hormonal Therapy
- By Indication:
- Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Esophagus Cancer
- Cervical Cancer
- Kidney Cancer
- Bladder Cancer
- Other Cancers
- Oncology Drugs Market dynamics
- Oncology Drugs Market size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved in the Market
- Value Chain of the Market
- Market Drivers and Restraints
Products
Table of Contents
Table of Contents
Contents
- Executive Summary
- Oncology Drugs Market
- Product Overview
- Market Definition
- Segmentation
- Assumptions and Acronyms
- Research Methodology
- Research Objectives
- Primary Research
- Secondary Research
- Forecast Model
- Market Size Estimation
- Average Pricing Analysis
- Market Dynamics
- Growth Drivers
- Restraints
- Opportunity
- Trends
- Correlation & Regression Analysis
- Correlation Matrix
- Regression Matrix
- Recent Development, Policies & Regulatory Landscape
- Risk Analysis
- Demand Risk Analysis
- Supply Risk Analysis
- Oncology Drugs Market Analysis
- Porters Five Forces
- Threat of New Entrants
- Bargaining Power of Suppliers
- Threat of Substitutes
- Rivalry
- PEST Analysis
- Political
- Economic
- Social
- Technological
- Porters Five Forces
- Oncology Drugs Market
- Market Size & forecast, 2019A-2030F
- By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Market Size & forecast, 2019A-2030F
- Oncology Drugs Market: Market Segmentation
- By Regions
- North America:(U.S. and Canada)
- By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
- By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
- By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
- By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
- By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- North America:(U.S. and Canada)
- By Regions
- Oncology Drugs Market: Market Segmentation
- By disease indication: Market Share (2020-2030F)
- Lung Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Stomach Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Colorectal Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Breast Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Prostate Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Liver Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Esophagus Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Cervical Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Kidney Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Bladder Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Other Cancers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- By type : Market Share (2020-2030F)
- Chemotherapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Targeted Therapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Immunotherapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Hormonal Therapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- By disease indication: Market Share (2020-2030F)
- Company Profile
- Bayer AG
- Company Overview
- Company Total Revenue (Financials)
- Market Potential
- Global Presence
- Key Performance Indicators
- SWOT Analysis
- Product Launch
- Genentech, Inc.
- Novartis AG
- Pfizer Inc.
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc.
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Other prominent players
- Bayer AG
- Consultant Recommendation
**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.